- Previous Close
0.0210 - Open
0.0210 - Bid 0.0200 x --
- Ask 0.0210 x --
- Day's Range
0.0210 - 0.0210 - 52 Week Range
0.0200 - 0.0690 - Volume
623,747 - Avg. Volume
1,342,713 - Market Cap (intraday)
15.719M - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. Its products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also offers disposable, Lumos Leelu, and hand-held readers. The company was incorporated in 2018 and is based in Carlsbad, California.
lumosdiagnostics.comRecent News: LDX.AX
View MorePerformance Overview: LDX.AX
Trailing total returns as of 3/12/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LDX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LDX.AX
View MoreValuation Measures
Market Cap
15.72M
Enterprise Value
19.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.51
Price/Book (mrq)
1.01
Enterprise Value/Revenue
0.83
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-33.97%
Return on Assets (ttm)
-13.86%
Return on Equity (ttm)
-52.41%
Revenue (ttm)
14.67M
Net Income Avi to Common (ttm)
-4.98M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
5.53M
Total Debt/Equity (mrq)
79.75%
Levered Free Cash Flow (ttm)
957.88k